Want to see IN:ALIVUS full AI Analyst Report?
ALIVUS Stock Chart & Stats
₹920.80
-₹16.95(-1.62%)
At close: 4:00 PM EST
₹920.80
-₹16.95(-1.62%)
Day’s Range― - ―
52-Week Range₹830.00 - ₹1,223.60
Previous CloseN/A
VolumeN/A
Average Volume (3M)7.13K
Market Cap
₹142.28B
Enterprise Value₹108.29K
Total Cash (Recent Filing)₹6.53B
Total Debt (Recent Filing)₹1.13B
Price to Earnings (P/E)23.6
Beta0.85
Next Earnings
Nov 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.43%
Share Statistics
EPS (TTM)22.17
Shares Outstanding122,739,450
10 Day Avg. Volume3,315
30 Day Avg. Volume7,125
Financial Highlights & Ratios
PEG Ratio1.32
Price to Book (P/B)3.59
Price to Sales (P/S)4.69
P/FCF Ratio46.15
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)54.28
Revenue Forecast (FY)₹28.31B
Bulls Say, Bears Say
Bulls Say
Revenue GrowthA large, durable revenue acceleration increases scale and customer relevance in the API market. Sustained higher volumes support fixed-cost absorption, reinforce supplier/customer relationships, and provide recurring cash to fund capacity, R&D and margin stability over the medium term.
High ProfitabilityConsistently strong operating and net margins reflect manufacturing efficiency and favorable product mix in specialty APIs. High margins create durable earnings power, enabling reinvestment, insulating profits from moderate price or cost swings, and supporting long-term return generation.
Conservative Balance SheetExtremely low leverage and solid ROE provide financial resilience and flexibility. This conservative structure lowers bankruptcy risk, preserves optionality for capex or M&A, and supports multi-quarter stability in capital allocation even if sector cycles soften.
Bears Say
Weak Cash ConversionLow free-cash-flow conversion versus reported earnings indicates earnings quality risk: working capital or non-cash items reduce cash available to fund growth or returns. Over several quarters this can constrain buybacks/dividends or require external financing for expansion.
Margin Volatility RiskNotable margin swings imply sensitivity to product mix, pricing and input costs common in APIs. Persistent volatility makes forward earnings less predictable and can erode the durability of high-margin outcomes if key products face price pressure or raw material inflation.
Working-capital/Capex AbsorptionOngoing capex and working-capital drains limit free cash available for discretionary uses and can force phased investment or external funding for capacity projects. Structurally high reinvestment needs reduce near-term financial flexibility and return-of-capital capacity.
Glenmark Life Sciences Limited News
ALIVUS FAQ
What was Glenmark Life Sciences Limited’s price range in the past 12 months?
Glenmark Life Sciences Limited lowest stock price was ₹830.00 and its highest was ₹1223.60 in the past 12 months.
What is Glenmark Life Sciences Limited’s market cap?
Glenmark Life Sciences Limited’s market cap is ₹142.28B.
When is Glenmark Life Sciences Limited’s upcoming earnings report date?
Glenmark Life Sciences Limited’s upcoming earnings report date is Nov 05, 2026 which is in 93 days.
How were Glenmark Life Sciences Limited’s earnings last quarter?
Glenmark Life Sciences Limited released its earnings results on Jul 30, 2026. The company reported ₹13 earnings per share for the quarter, beating the consensus estimate of ₹12.1 by ₹0.9.
Is Glenmark Life Sciences Limited overvalued?
According to Wall Street analysts Glenmark Life Sciences Limited’s price is currently Overvalued.
Does Glenmark Life Sciences Limited pay dividends?
Glenmark Life Sciences Limited pays a Semiannually dividend of ₹5 which represents an annual dividend yield of 0.43%. See more information on Glenmark Life Sciences Limited dividends here
What is Glenmark Life Sciences Limited’s EPS estimate?
Glenmark Life Sciences Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Glenmark Life Sciences Limited have?
Glenmark Life Sciences Limited has 122,739,450 shares outstanding.
What happened to Glenmark Life Sciences Limited’s price movement after its last earnings report?
Glenmark Life Sciences Limited reported an EPS of ₹13 in its last earnings report, beating expectations of ₹12.1. Following the earnings report the stock price went down -2.166%.
Which hedge fund is a major shareholder of Glenmark Life Sciences Limited?
Currently, no hedge funds are holding shares in IN:ALIVUS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Glenmark Life Sciences Limited
Alivus Life Sciences Limited, a Mumbai, India-headquartered entity established in 2001, operates as a subsidiary of Nirma Limited. Having rebranded from Glenmark Life Sciences Limited in December 2024, the company specializes in the development, production, and global commercialization of active pharmaceutical ingredients (APIs). Its market footprint spans India, Japan, Europe, and both North and Latin America, supported by substantial export operations. Alivus Life Sciences provides an extensive catalog of APIs, including olmesartan, telmisartan, solifenacin, sitagliptin, zonisamide, rosuvastatin, amiodarone, ezetimibe, lithium carbonate, oxcarbazepine, mirabegron, atovaquone, etoricoxib, remogliflozin, cabozantinib, and palbociclib. These ingredients are utilized across a diverse array of therapeutic areas, such as cardiovascular diseases, central nervous system disorders, diabetes, gastrointestinal health, oncology, pain management, immunosuppression, respiratory and ophthalmological conditions, urology, and anti-infectives. Additionally, the company extends its expertise by offering contract development and manufacturing services (CDMO) to numerous multinational corporations and specialty pharmaceutical enterprises.
Technical Analysis
Divi's Laboratories Limited
―
Granules India Limited
―
Laurus Labs Ltd.
―
Neuland Laboratories Ltd.
―
Solara Active Pharma Sciences Ltd.
―